TORONTO, ON / CRWEPRESSRELEASE / August 4, 2015 / ChroMedX Corp. (CNSX:CHX) (OTCMKTS:MNLIF) (FRA:EIY2.F) (the “Company“), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce that its common shares recently commenced trading on the OTCQB(R), under the symbol “MNLIF.” Real-time quotes and market information on the Company are available at http://www.otcmarkets.com/stock/MNLIF/quote
“We are very pleased to be listed on the OTCQB and to have our shares more easily accessible to the US marketplace.” said Wayne Maddever, President & CEO, ChroMedX Corp.
The OTCQB, a US trading platform operated by the OTC Markets Group in New York, is a venture stage marketplace for early-stage and developing U.S. and international companies. Companies are required to meet eligibility standards aimed at improving the information available to investors. OTCQB includes real-time level 2 quotes and the OTC disclosure and news service to help companies improve information experience to their investors.
ChroMedX Corp.’s common shares continue to trade on the Canadian Securities Exchange under the symbol “CHX.”
For more information you can visit the ChroMedX Corp. website: www.ChroMedX.com
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company’s issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.
Follow ChroMedX Corp.:
W. Clark Kent
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com.
SOURCE: ChroMedX Corp.